drugset

Drugs / KVA12123

Follow last change Dec 2025 re-read 3 minutes ago

KVA12123

also known as TBS-2025

Developed for: breast cancer · carcinoma · colorectal cancer · esophageal cancer · gastric cancer · head and neck cancer · kidney cancer · lung cancer
+7 more
· malignant pancreatic neoplasm · melanoma · ovarian cancer · prostate cancer · sarcoma · thyroid cancer · uterine cancer
Investigated by: Kineta Inc. · Merck Sharp & Dohme LLC

Trials 1

today NCT05708950 · Ph 1/2

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT05708950	Mar 2023 → Oct 2025	breast cancer, carcinoma, colorectal cancer, esophageal cancer +11	Kineta Inc.	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	KVA12123	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05708950 ↗
Known as	TBS-2025	“A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)” NCT05708950 ↗
Route	Intravenous	“KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle” NCT05708950 ↗